Eyetech Pharmaceuticals About
Eyetech Eyetech Pharmaceuticals, Inc. is a biopharmaceutical
company that specializes in the development and commercialization of novel therapeutics
to treat diseases of the eye. The initial focus is on diseases affecting the back
of the eye, particularly the retina. Their
most advanced product candidate is Macugen® (pegaptanib sodium injection)™
(pegaptanib sodium injection), which they are developing for the treatment of
the wet form of age-related macular
degeneration, known as AMD, and diabetic macular edema, known as DME. Both
AMD and DME are serious diseases of the retina that can lead to severe vision
loss and blindness. Clinical
Trials for Eyetech Pharmaceuticals Two Phase 2/3 pivotal
clinical trials for the use of Macugen® (pegaptanib sodium injection) in
the treatment of wet AMD and a Phase 2 clinical trial of Macugen® (pegaptanib
sodium injection) for the use of Macugen® (pegaptanib sodium injection) in the
treatment of DME. More
on Eyetech Key
Statistics for Eyetech
Basic
Chart for Eyetech